Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting

September 17, 2019

The ODM DUR Board meeting was called to order at 11.59 AM EST in room C621 A&B 50 West Town Street, Columbus, Ohio. A. Mehran Mostafavifar, M.D. presided.

The following Board members were present:
- Michelle Barger, Pharm.D.
- David Brookover, R.Ph.
- Michael Dietz, D.O., Co-Chair.
- Robert Kubasak, R.Ph.
- A. Mehran Mostafavifar, M.D., Chair.
- Lenard Presutti, D.O.
- Stacey Rexrode-Brewer, Pharm.D.
- Donald Sullivan, Ph.D., R.PH

Also present from ODM were Tracey Archibald, Pharm.D., and Scott Baran, R.Ph. Change Healthcare attendees included Jill R.K. Griffith B.S. Pharm.D., and Gail Master, R.Ph. Approximately 21 observers were present, mostly representing pharmaceutical manufacturers.

Roll Call, Reading, Correction, and Approval of Previous Minutes

The May 14, 2019 DUR Board Meeting minutes were approved.

DUR Committee Report

G. Master presented a summary of the RetroDUR intervention directed at members who received a prescription for Tamiflu but who did not receive a flu shot during the subsequent flu season.

G. Master presented the re-review results from the RetroDUR intervention directed at the prescribers of patients who were taking greater than 400 morphine equivalent doses (MED) of opioids per day.

G. Master presented the re-review results from the RetroDUR intervention directed at the prescribers of patients who were taking muscle relaxants for greater than 90 days.

G. Master provided an update to the Board on the Coordinated Services Program (CSP) membership. Currently, 204 Fee-for-Service members are enrolled in the program and nineteen new members will be enrolled on October 1, 2019. She outlined the re-enrollment process after a member has been enrolled in the program for 24 months.
M. Barger announced that The Ohio Department of Medicaid (ODM) is moving forward with the Unified Preferred Drug List (formerly called Single PDL). Implementation is scheduled for January 1st, 2020, and that plans are to move forward with the entire PDL. ODM continues to work the Managed Care Plans through a series of workgroups in order to help ensure a smooth transition. The draft Unified PDL will be posted to the pharmacy website on September 18, 2019.

There were several pharmacy related initiatives included in the most recent state budget. These items included: adopting rules to provide a supplemental dispensing fee under the care management system to retail pharmacies, as well as selecting a state pharmacy benefit manager to be used by all managed care organizations (which shall be selected provisionally no later than July 1, 2020). Both of these initiatives are in the early stages of development, so expect more details at a later date.

Last month CMS issued guidance to the states concerning implementation of the new Medicaid DUR provisions that were included in Section 1004 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, also referred to as the SUPPORT Act. The guidance addressed the following requirements: opioid prescription claim reviews at the point of sale and retrospective reviews; monitoring and management of antipsychotic medication in children; identification of processes to detect fraud and abuse, mandatory DUR report updates, as well as requirements for Medicaid Managed Care Organizations. Each state must submit a State Plan Amendment by the end of this year, which the Department is currently working on.

And finally, since we met last, the Annual Drug Utilization Review Report has been submitted to CMS. This report will be posted to the Medicaid.gov website later this year. As a reminder, this was the first year where in addition to the Fee-For-Service report, managed Care Plans were required to submit reports as well.

Unfinished Business

G. Master provided an update on the DUR Drug-Drug interactions and directed the Board to a list of less severe drug-drug interactions that will be suppressed.

G. Master provided an update on the original container edit and explained that this will be incorporated into a retrospective claims review.

New Business

G. Master introduced background information on adherence to atypical antipsychotic medications. The Board cautioned that many prescribers are fatigued by the amount of mail they are receiving. A discussion ensued around the average adherence rate to atypical antipsychotics and the set of population that drives this non-adherence. The DUR Board was in favor of sending letters to prescribers whose patients are less than eighteen years old and are at seventy percent or less adherent, and prescribers whose patients are greater than eighteen years old and are at fifty percent or less adherent. Next, the prescriber letter was reviewed.
G. Master introduced the concept of prescriber report cards/benchmarking. A discussion ensued around what categories of drugs should be targeted. The DUR Board was in favor of looking at appropriate diagnosis codes for select medications. G. Master explained that the DUR Committee will be discussing this in detail next month and additional information will be presented to the Board at the next meeting in November.

Announcements

Per A. Mostafavifar, ODM Director Maureen Corcoran will be speaking at The Ohio State University on October 11th, at the Fawcett Center.

The dates for the next DUR Board meetings were set as follows:

- November 12, 2019
- February 11, 2020
- May 12, 2020
- September 15, 2020
- November 10, 2020

Adjournment

Dr. Mostafavifar adjourned the meeting at 1:00 P.M.